1: Bisaglia M, Greggio E, Beltramini M, Bubacco L. Dysfunction of dopamine
homeostasis: clues in the hunt for novel Parkinson's disease therapies. FASEB J.
2013 Jun;27(6):2101-10. doi: 10.1096/fj.12-226852. Epub 2013 Mar 5
2: Codolo G, Plotegher N, Pozzobon T, Brucale M, Tessari I, Bubacco L, de Bernard
M. Triggering of inflammasome by aggregated α-synuclein, an inflammatory response
in synucleinopathies. PLoS One. 2013;8(1):e55375.
3: Bochot C, Favre E, Dubois C, Baptiste B, Bubacco L, Carrupt PA, Gellon G,
Hardrì R, Luneau D, Moreau Y, Nurisso A, R√©glier M, Serratrice G, Belle C, Jamet
H. Unsymmetrical binding modes of the HOPNO inhibitor of tyrosinase: from model
complexes to the enzyme. Chemistry. 2013 Mar 11;19(11):3655-64.
4: Pivato M, De Franceschi G, Tosatto L, Frare E, Kumar D, Aioanei D, Brucale M,
Tessari I, Bisaglia M, Samori B, de Laureto PP, Bubacco L. Covalent a-synuclein
dimers: chemico-physical and aggregation properties. PLoS One. 2012;7(12):e50027.
doi: 10.1371/journal.pone.0050027.
5: Biosa A, Trancikova A, Civiero L, Glauser L, Bubacco L, Greggio E, Moore DJ.
GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's
disease-associated LRRK2. Hum Mol Genet. 2013 Mar 15;22(6):1140-56.
6: Ferrari E, Engelen M, Monzani E, Sturini M, Girotto S, Bubacco L, Zecca L,
Casella L. Synthesis and structural characterization of soluble neuromelanin
analogs provides important clues to its biosynthesis. J Biol Inorg Chem. 2013
Jan;18(1):81-93. doi: 10.1007/s00775-012-0951-7.
7: Civiero L, Vancraenenbroeck R, Belluzzi E, Beilina A, Lobbestael E, Reyniers
L, Gao F, Micetic I, De Maeyer M, Bubacco L, Baekelandt V, Cookson MR, Greggio E,
Taymans JM. Biochemical characterization of highly purified leucine-rich repeat
kinases 1 and 2 demonstrates formation of homodimers. PLoS One. 2012;7(8):e43472.
doi: 10.1371/journal.pone.0043472.
8: Tosatto L, Andrighetti AO, Plotegher N, Antonini V, Tessari I, Ricci L,
Bubacco L, Dalla Serra M. Alpha-synuclein pore forming activity upon membrane
association. Biochim Biophys Acta. 2012 Nov;1818(11):2876-83.
9: Belluzzi E, Bisaglia M, Lazzarini E, Tabares LC, Beltramini M, Bubacco L.
Human SOD2 modification by dopamine quinones affects enzymatic activity by
promoting its aggregation: possible implications for Parkinson's disease. PLoS
One. 2012;7(6):e38026.
10: Greggio E, Civiero L, Bisaglia M, Bubacco L. Parkinson's disease and immune
system: is the culprit LRRKing in the periphery? J Neuroinflammation. 2012 Jul
9;9:94
Girotto S, Sturlese M, Bellanda M, Tessari I, Cappellini R, Bisaglia M,
Bubacco L, Mammi S. Dopamine-derived quinones affect the structure of the redox
sensor DJ-1 through modifications at Cys-106 and Cys-53. J Biol Chem. 2012 May
25;287(22):18738-49
12: Aioanei D, Brucale M, Tessari I, Bubacco L, Samorì B. Worm-like Ising model
for protein mechanical unfolding under the effect of osmolytes. Biophys J. 2012
Jan 18;102(2):342-50.